He Xun Cai Jing·2025-05-07 14:57Financial Performance - BeiGene reported a net loss of 945.03 million yuan in Q1 2025, despite a significant increase in product revenue [2] - The company's product revenue reached 7.985 billion yuan, a year-on-year increase of 49.9%, while total revenue was 8.048 billion yuan, up 50.2% year-on-year [2] - Total assets at the end of the reporting period were 42.126 billion yuan, a decrease of 1.7% from the beginning of the period, while equity attributable to shareholders increased by 4.3% to 25.206 billion yuan [2] Product Sales Growth - The growth in product revenue was primarily driven by self-developed products such as Brukinsa® (Zebutinib) and Tazverik® (Tazemetostat), along with sales growth from Amgen's licensed products [3] - Global sales of Brukinsa® totaled 5.692 billion yuan, a year-on-year increase of 63.7%, with U.S. sales at 4.041 billion yuan, up 61.9% [3] - Sales in Europe reached 836 million yuan, a 75.4% increase, while sales in China were 590 million yuan, up 43.1% [3] - Sales of Tazverik® amounted to 1.245 billion yuan, reflecting a year-on-year growth of 19.3%, driven by new patient demand from newly approved indications in China [3] Corporate Governance and Changes - The controlling shareholder of Dongxing Securities will change to Huijin Company following the approval of a state-owned equity transfer plan [5] - Haohai Biological Technology announced that its controlling shareholder, Jiang Wei, is under investigation for insider trading, although this matter does not impact the company's daily operations [4]